Read More Pharma Industry News PMV’s $79.4m cash pile now hinges on rezatapopt’s 2027 ovarian cancer FDA bid PMV completes key rezatapopt enrollment with a 2027 FDA filing ahead as its $79.4m cash balance exceeds its current market value. bySoujanya RaviAugust 16, 2026